Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Empirical evaluation of the sensitivity of background incidence rate characterization for adverse events across an international observational data network

View ORCID ProfileAnna Ostropolets, View ORCID ProfileXintong Li, Rupa Makadia, Gowtham Rao, Peter R. Rijnbeek, View ORCID ProfileTalita Duarte-Salles, View ORCID ProfileAnthony G. Sena, Azza Shaoibi, View ORCID ProfileMarc A. Suchard, Patrick B. Ryan, View ORCID ProfileDaniel Prieto-Alhambra, George Hripcsak
doi: https://doi.org/10.1101/2021.06.27.21258701
Anna Ostropolets
1Columbia University Medical Center, New York, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Anna Ostropolets
Xintong Li
2Centre for Statistics in Medicine, NDORMS, University of Oxford, Oxford, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Xintong Li
Rupa Makadia
3Janssen Research and Development, Titusville, NJ, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gowtham Rao
3Janssen Research and Development, Titusville, NJ, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter R. Rijnbeek
4Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Talita Duarte-Salles
5Fundacio Institut Universitari per a la recerca a l’Atencio Primaria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Talita Duarte-Salles
Anthony G. Sena
3Janssen Research and Development, Titusville, NJ, USA
4Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Anthony G. Sena
Azza Shaoibi
3Janssen Research and Development, Titusville, NJ, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marc A. Suchard
6Department of Biostatistics, Fielding School of Public Health, University of California, Los Angeles, CA, USA
7Department of Human Genetics, David Geffen School of Medicine at UCLA, University of California, Los Angeles, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Marc A. Suchard
Patrick B. Ryan
1Columbia University Medical Center, New York, NY, USA
3Janssen Research and Development, Titusville, NJ, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel Prieto-Alhambra
2Centre for Statistics in Medicine, NDORMS, University of Oxford, Oxford, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Daniel Prieto-Alhambra
George Hripcsak
1Columbia University Medical Center, New York, NY, USA
8New York-Presbyterian Hospital, New York, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: gh13@cumc.columbia.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Background incidence rates are routinely used in safety studies to evaluate the association of an exposure and an outcome. Systematic research on the sensitivity of background rates to the choice of the study parameters is lacking. We used 12 electronic health record and administrative claims data sources to calculate incidence rates of 15 adverse events. We examined the influence of age, race, sex, database, time-at-risk start (anchoring) event and duration, season and year, prior observation and clean window. For binary comparisons, we calculated incidence rate ratios and performed random-effect model meta-analysis. Background rates were highly sensitive to demographic characteristics of the population, especially age, with rates varying up to a factor of 1,000 across age groups. Rates varied by up to a factor of 100 by database. Incidence rates were highly influenced by the choice of anchoring (e.g., health visit, vaccination, or arbitrary date) for the time-at-risk start, especially at short times at risk, and less influenced by secular or seasonal trends. Therefore, comparing background to observed rates requires appropriate adjustment, and results should be interpreted in the context of design choices.

Figure
  • Download figure
  • Open in new tab

Competing Interest Statement

GH and AO receive funding from the US National Institutes of Health (NIH) and the US Food and Drug Administration. DPA research group has received research grants from the European Medicines Agency; the Innovative Medicines Initiative; Amgen, Chiesi, and UCB Biopharma; and consultancy or speaker fees from Astellas, Amgen, Astra Zeneca, and UCB Biopharma. PR works for a research group that receives/received unconditional research grants from Yamanouchi, Pfizer-Boehringer Ingelheim, Novartis, GSK, Amgen, and Chiesi, none of which relates to the content of this paper. PBR, RM, AS, GR, and AGS are employees of Janssen Research and Development and shareholders in Johnson and Johnson. MAS receives grants and contracts from the FDA and the US Department of Veterans Affairs within the scope of this research, and grants and contracts from NIH, IQVIA, and Private Health Management outside the scope of this research.

Funding Statement

US National Library of Medicine (R01 LM006910), US Food and Drug Administration CBER BEST Initiative (75F40120D00039), UK National Institute of Health Research (NIHR), European Medicines Agency, Innovative Medicines Initiative 2 (806968).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The protocol for this research was approved by the Columbia University Institutional Review Board (AAAO7805), the Independent Scientific Advisory Committee (ISAC) for MHRA Database Research (20_000211), the IDIAPJGol Clinical Research Ethics Committee (project code: 21/007-PCV), the IPCI governance board (application number 3/2021).

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • ↵* Joint first authors

Data Availability

Patient-level data cannot be shared without approval from data custodians due to local information governance and data protection regulations. Aggregated data, analytical code, and detailed definitions of algorithms for identifying the events are available in a GitHub repository (https://github.com/ohdsi-studies/Covid19VaccineAesiIncidenceCharacterization).

https://github.com/ohdsi-studies/Covid19VaccineAesiIncidenceCharacterization

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted July 02, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Empirical evaluation of the sensitivity of background incidence rate characterization for adverse events across an international observational data network
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Empirical evaluation of the sensitivity of background incidence rate characterization for adverse events across an international observational data network
Anna Ostropolets, Xintong Li, Rupa Makadia, Gowtham Rao, Peter R. Rijnbeek, Talita Duarte-Salles, Anthony G. Sena, Azza Shaoibi, Marc A. Suchard, Patrick B. Ryan, Daniel Prieto-Alhambra, George Hripcsak
medRxiv 2021.06.27.21258701; doi: https://doi.org/10.1101/2021.06.27.21258701
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Empirical evaluation of the sensitivity of background incidence rate characterization for adverse events across an international observational data network
Anna Ostropolets, Xintong Li, Rupa Makadia, Gowtham Rao, Peter R. Rijnbeek, Talita Duarte-Salles, Anthony G. Sena, Azza Shaoibi, Marc A. Suchard, Patrick B. Ryan, Daniel Prieto-Alhambra, George Hripcsak
medRxiv 2021.06.27.21258701; doi: https://doi.org/10.1101/2021.06.27.21258701

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Health Informatics
Subject Areas
All Articles
  • Addiction Medicine (179)
  • Allergy and Immunology (431)
  • Anesthesia (99)
  • Cardiovascular Medicine (942)
  • Dentistry and Oral Medicine (178)
  • Dermatology (109)
  • Emergency Medicine (260)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (418)
  • Epidemiology (8968)
  • Forensic Medicine (4)
  • Gastroenterology (418)
  • Genetic and Genomic Medicine (1938)
  • Geriatric Medicine (190)
  • Health Economics (400)
  • Health Informatics (1322)
  • Health Policy (657)
  • Health Systems and Quality Improvement (517)
  • Hematology (211)
  • HIV/AIDS (416)
  • Infectious Diseases (except HIV/AIDS) (10766)
  • Intensive Care and Critical Care Medicine (570)
  • Medical Education (199)
  • Medical Ethics (52)
  • Nephrology (221)
  • Neurology (1818)
  • Nursing (108)
  • Nutrition (271)
  • Obstetrics and Gynecology (351)
  • Occupational and Environmental Health (469)
  • Oncology (992)
  • Ophthalmology (296)
  • Orthopedics (111)
  • Otolaryngology (182)
  • Pain Medicine (126)
  • Palliative Medicine (44)
  • Pathology (265)
  • Pediatrics (576)
  • Pharmacology and Therapeutics (275)
  • Primary Care Research (234)
  • Psychiatry and Clinical Psychology (1891)
  • Public and Global Health (4108)
  • Radiology and Imaging (674)
  • Rehabilitation Medicine and Physical Therapy (362)
  • Respiratory Medicine (547)
  • Rheumatology (224)
  • Sexual and Reproductive Health (190)
  • Sports Medicine (177)
  • Surgery (206)
  • Toxicology (38)
  • Transplantation (109)
  • Urology (80)